

2026 American Society of Clinical
Oncology Annual Meeting

Servier Pharmaceuticals Highlighted Abstracts

SERVIER 

SERVIER AT ASCO 2026

Highlighted Abstracts

Title

SATURDAY, MAY 30 | 9:00 AM–12:00 PM CDT

First-line NALIRIFOX in patients with metastatic pancreatic ductal adenocarcinoma and pre-existing diabetes: NAPOLI 3 post hoc analysis.

SUNDAY, MAY 31 | 9:00 AM–12:00 PM CDT

Neoadjuvant darovasertib in uveal melanoma patients undergoing primary local therapy (OptimUM-10): Phase 3 trial.

SUNDAY, MAY 31 | 4:36–4:42 PM CDT

A global, randomized, double-blinded, phase 3 trial of vorasidenib vs placebo in patients with grade 2 glioma with an *IDH1/2* mutation (INDIGO): updated efficacy and safety.

MONDAY, JUNE 1 | 8:24–8:36 AM CDT

Emiltatug ledadotin (Emi-Le), a B7-H4-directed antibody-drug conjugate (ADC), in patients with aggressive adenoid cystic carcinoma (ACC): Phase 1 interim analysis.

MONDAY, JUNE 1 | 9:00–9:12 AM CDT

Darovasertib plus crizotinib vs investigator's choice as first-line treatment for patients with HLA-A2 negative metastatic uveal melanoma: Primary results from the OptimUM-02 trial.

MONDAY, JUNE 1 | 9:00 AM–12:00 PM CDT

Preliminary results of an open-label, single-arm phase 2/3 trial (SPARK-ALL) of calaspargase pegol in adults with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia.

MONDAY, JUNE 1 | 1:30–4:30 PM CDT

Impact of vorasidenib vs placebo on seizure rates and quality of life: Exploratory analysis from phase 3 INDIGO study.

ONLINE ABSTRACT

Clinical and real-world trial comparison in *midH1* CCA patients treated with ivosidenib: ClarIDHy vs ProVIDHe.

Presentation

POSTER PRESENTATION

Dr. S. Chandana, MD, PhD

START Midwest

POSTER PRESENTATION

Dr. M. McKean

Sarah Cannon Research Institute

RAPID ORAL PRESENTATION

Dr. T. Cloughesy, MD

University of California, Los Angeles

ORAL PRESENTATION

Dr. G. J. Hanna, MD

Dana-Farber Cancer Institute

ORAL PRESENTATION

Dr. M. Orloff, MD

Thomas Jefferson Hospital

POSTER PRESENTATION

Dr. D. J. DeAngelo, MD, PhD

Dana-Farber Cancer Institute

POSTER PRESENTATION

Dr. W. Wick, MD

Universitätsklinikum Heidelberg & German Cancer Research Center

ONLINE ABSTRACT

Dr. H. Taghizadeh, MD, PhD

Medical University of Vienna

SERVIER AT ASCO 2026

Highlighted Abstracts

Title

ONLINE ABSTRACT

Real-World Assessment of Treatment Adherence among Vorasidenib-Treated Patients With IDH-mutant Glioma.

ONLINE ABSTRACT

Management of chemotherapy-induced adverse events in patients with metastatic pancreatic ductal adenocarcinoma: A US-based modified Delphi consensus.

ONLINE ABSTRACT

Incidence, severity, and management of severe adverse events in first-line (1L) treatments for metastatic pancreatic ductal adenocarcinoma (mPDAC): A retrospective observational study.

Investigator Sponsored Abstracts

MONDAY, JUNE 1 | 1:30–4:30 PM CDT

Alliance A072301: A phase III trial of radiotherapy followed by adjuvant temozolomide in combination with vorasidenib vs placebo in IDH-mutated newly diagnosed grade 3 astrocytoma (VORTEX).

TUESDAY, JUNE 2 | 10:45–10:57 AM CDT

A multicenter, phase Ib/II trial of azacitidine, venetoclax, ivosidenib in IDH1-mutated acute myeloid leukemia (AML).

Presentation

ONLINE ABSTRACT

Q. Xu, PhD, MS

Servier Pharmaceuticals

ONLINE ABSTRACT

Dr. M. Hussein, MD

*Florida Cancer Specialists
& Research Institute*

ONLINE ABSTRACT

Dr. R. R. McWilliams, MD

Mayo Clinic Rochester

POSTER PRESENTATION

Dr. U. Chukwueke, MD, MPH

Dana-Farber Cancer Institute

ORAL PRESENTATION

Dr. J. Marvin-Peek, MD

*University of Texas MD Anderson
Cancer Center*